Tianeptine

Tianeptine is a small-molecule drug of the tricyclic antidepressant chemical family, though its pharmacology sets it apart from the classic tricyclics. It was developed in France and has been prescribed since the late 1980s, chiefly for major depressive disorder and associated anxiety, and it has also been used for conditions such as irritable bowel syndrome ^[1]. It is marketed under names including Stablon, Coaxil, and Tatinol in countries across Europe, Asia, and Latin America, but it has never been approved in a number of Western countries, including the United States, Canada, the United Kingdom, and Australia ^[1]. It is used in the form of salts, most commonly tianeptine sodium in approved medicines, while unregulated products often contain tianeptine sulfate or the free acid.

For decades tianeptine's mechanism was a puzzle. Early descriptions cast it as a serotonin reuptake enhancer, the opposite of the reuptake inhibition of standard antidepressants, but this did not adequately explain its effects. In 2014 researchers identified tianeptine as an efficacious agonist at the mu-opioid receptor and a weaker full agonist at the delta-opioid receptor, with no meaningful activity at the kappa-opioid receptor, proposing that opioid receptor activation is the initial trigger for its antidepressant and anti-anxiety actions ^[2]. Later studies in mice confirmed that the antidepressant-like effects of tianeptine require the mu-opioid receptor and traced them to specific brain circuits, while noting that its metabolism yields a longer-lasting active product ^[3][4].

The recognition of tianeptine as an opioid receptor agonist reframed its safety profile. At doses far above those used therapeutically, tianeptine produces opioid-like euphoria and carries a real potential for abuse and dependence, and stopping it after heavy use can provoke a withdrawal syndrome resembling opioid withdrawal ^[1]. In the United States, where it is not an approved drug, it has been sold in gas stations and convenience stores as a supplement or research chemical, earning the nickname gas station heroin; the Food and Drug Administration has warned about adulterated products and serious harms, and a number of individual states have banned it or placed it under controlled-substance schedules ^[1]. Regulatory reclassifications and outright bans have been expanding internationally as recreational use grows ^[1].

At therapeutic doses within approved medical systems, tianeptine has generally been reported to have a favorable tolerability profile compared with older tricyclics, with side effects such as headache, insomnia, dry mouth, and constipation, and rare reports of liver injury ^[1]. Its dual identity, as an established prescription antidepressant in some countries and an abused, unregulated substance in others, makes it an unusual case in modern pharmacology. Because of the opioid mechanism and the associated risks of dependence and overdose, particularly when combined with other central-nervous-system depressants, its non-medical use is considered hazardous ^[1][2].

Tianeptine is an approved prescription antidepressant across parts of Europe, Asia, and Latin America, but it is not approved by the FDA in the United States, where it is sold unregulated in supplements and gas stations and has earned the nickname gas station heroin. At the normal low dose the side effects are mild: nausea, constipation, dry mouth, dizziness, and trouble sleeping. The real hazard shows up at high, above-label doses, where the mu-opioid activity takes over and can produce euphoria, tolerance, dependence, opioid-style withdrawal, and even slowed breathing and overdose that may need naloxone to reverse. It should never be combined with MAO inhibitors, and it calls for real caution alongside other opioids and central nervous system depressants.

Tianeptine was developed in France in the 1960s and brought to market by the pharmaceutical company Servier, becoming available from the late 1980s as an atypical antidepressant under brand names including Stablon, Coaxil, and Tatinol. It was distinctive from the outset because, contrary to prevailing theory, it appeared to enhance rather than block serotonin reuptake, and later research reframed its action around modulation of glutamatergic neurotransmission and neuroplasticity in stress-related brain circuits.

A further pharmacological insight came in the 2010s, when investigators demonstrated that tianeptine is a full agonist at the mu-opioid receptor, a finding that helped explain both its clinical profile and its potential for misuse. It has been prescribed for depression and anxiety in numerous European, Asian, and Latin American countries, but was never approved as a medicine in the United States.

Tianeptine has a sharply divided reputation. In the clinical settings where it is approved, it is regarded as an effective and generally well-tolerated antidepressant with an unusual mechanism, sometimes favored for patients with comorbid anxiety. Outside those settings, particularly in the United States where it is unapproved, it has acquired a very different and largely negative image as a substance of abuse, sold in gas stations and online and nicknamed gas station heroin, owing to its mu-opioid agonism and the dependence, escalating use, and dangerous withdrawal that can follow supratherapeutic dosing.

Regulators and poison-control authorities have issued repeated warnings, and several jurisdictions have restricted or banned it. The result is a compound viewed by clinicians in approving countries as a legitimate therapy and by public-health officials elsewhere as a serious risk when taken recreationally.